Cathepsin S: From Molecular Regulation to Therapeutic Targeting, New Horizons for Selective Inhibition
Cathepsin S (CatS) is a protease that, unlike most human cysteine cathepsins, remains active at neutral pH, enabling functions in both the endolysosomal compartment and the extracellular space. It primes antigen presentation, remodels the extracellular matrix, and cleaves cytokines and receptors, placing it at the heart of inflammation, autoimmunity, pain, and cancer when its expression or activity is dysregulated. Despite the setbacks of CatK inhibitors, which warn against complete protease shutdown, the approval of brensocatib (a CatC/DPP1 inhibitor) for bronchiectasis supports the feasibility of therapeutic targeting of CatS. This review dissects how CatS is regulated, maps its substrates and roles in disease, and updates the landscape of natural and synthetic inhibitors that bind inside or outside the active site of the enzyme. Finally, it discusses emerging strategies for selective modulation of CatS activity.
Authors
- Ahlame Saidi (ORCID: https://orcid.org/0000-0002-0282-2476)
- Florian Veillard (ORCID: https://orcid.org/0000-0003-1248-2396)
- Alexis David (ORCID: https://orcid.org/0009-0008-7623-7131)
- Gilles Lalmanach (ORCID: https://orcid.org/0000-0001-8562-4821)
- Fabien Lecaille (ORCID: https://orcid.org/0000-0003-1060-4222)
- Clarisse Brossier (ORCID: https://orcid.org/0000-0002-8686-4883)
- Jasmine Imbert
Institutions
- Université de Tours (FR)
- Inserm (FR)
Publication Details
- Journal
- Biomolecules
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3390/biom16111683
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00